Patient-reported outcome data support perioperative durvalumab for operable NSCLC
09 May 2025
byJairia Dela Cruz
In patients with resectable nonsmall cell lung cancer (NSCLC), adding perioperative durvalumab to neoadjuvant chemotherapy does not appear to have a detrimental impact on patient-reported health-related quality of life (QoL), functioning, or symptoms as compared with neoadjuvant chemotherapy alone, according to data from the phase III AEGEAN study.